Home > Press release > Chiesi Farmaceutici President appointed Knight of...

Autorizzo al trattamento dei miei dati personali
ai sensi del D.L. 30 giugno 2003 n. 196
Edit email address
Invalid email
Your request has been sent successfully
Authorize the processing of personal data

Chiesi Farmaceutici President appointed Knight of the Légion d’Honneur

Date: 18/09/2020

Parma, 18th September 2020 – Chiesi Farmaceutici, an international research-focussed group, announces the appointment of Dr. Alberto Chiesi, President of the Group, to Knight of the Légion d’Honneur, the highest order of merit awarded by the Republic of France.

The appointment, which was established by a Decree of the French President dated 16th August 2019, was made official yesterday during a ceremony held at the Senate of the French Republic in Paris and attended by Jacqueline Gourault, Minister for Territorial Cohesion and relations with local authorities.

My thanks go to the French authorities for this important acknowledgement, which for me means a significant result linked to our Group’s ability to successfully relate to the territories where it operates. - commented Dr. Alberto Chiesi, President of the Group, at the ceremony - Chiesi is a family-run company set up 85 years ago in Parma, where its headquarters are still located today along with its main Research Centre and production plant. It remains closely linked to the values of its founder, Giacomo Chiesi, which means listening to patients, scientific creativity and entrepreneurial spirit. I believe that Chiesi France represents a fundamental example of Franco-Italian friendship, a success story that I am sure has a long future”.  

One of Chiesi’s 29 affiliates is located in France, along with one of its 3 production plants in the Loir-et-Cher region, where the company has continued to invest since the affiliate was set up in 1992.


The Chiesi Group 

Based in Parma, Italy, Chiesi Farmaceutici is an international research-oriented group with 85 years’ experience in the pharmaceutical sector, operating in 29 countries. The Group conducts research and develops and markets innovative drugs for respiratory treatment, Special Care medicine and rare diseases. The Group’s Research and Development Centre is based in Parma and is integrated with 4 other important R&D centres in France, the USA, the UK and Sweden to promote its own pre-clinical, clinical and regulatory programmes. The Group employs around 6,000 people. Chiesi has been a certified B Corp since 2019: this means it is required by law to take into account the impact its decisions have on its employees, clients, suppliers, communities and the environment. It is a global movement that views business as a force for good. The company has also committed to becoming carbon neutral, generating zero environmental impact, by the end of 2035.


Contacts for the press:

Giovanna Usvardi
Global Communication & Public Affairs Head

Tel: +39 3400875248

Email: g.usvardi@chiesi.com


Alessio Pappagallo

Global Communication Manager

Tel: +39 339 5897483

Email: a.pappagallo@chiesi.com